Skip to main content

BG Medicine, Inc. (BGMD)

OTCMKTS: BGMD · Delayed Price · USD
0.0218 0.0018 (9.00%)
Sep 9, 2021 12:43 PM EDT - Market open
Market Cap545,969
Revenue (ttm)1.57M
Net Income (ttm)-6.96M
Shares Out11.37M
EPS (ttm)-0.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,795
Open0.0111
Previous Close0.0200
Day's Range0.0218 - 0.0218
52-Week Range0.0101 - 0.1900
Beta0.78
Analystsn/a
Price Target1.40 (+6,322.0%)
Est. Earnings Daten/a

About BGMD

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and is...

IndustryLife Sciences Tools & Services
IPO DateFeb 4, 2011
CEOPaul Sohmer
Employees5
Stock ExchangeOTCMKTS
Ticker SymbolBGMD
Full Company Profile

Financial Performance

In 2015, BG Medicine's revenue was $1.57 million, a decrease of -43.81% compared to the previous year's $2.79 million. Losses were -$5.30 million, -34.24% less than in 2014.

Financial Statements

News

There is no news available yet.